Stockhouse: Optimi Health cleared to supply MDMA and psilocybin worldwide

By Trevor Abes

  • Optimi Health (CSE:OPTI), a microcap psychedelics manufacturer, has been awarded a Drug Establishment Licence from Health Canada to produce and sell its MDMA and psilocybin capsules to an Australian client
  • The designation certifies that the company is compliant with Good Manufacturing Practices, allowing it to manufacture, export and distribute its MDMA and psilocybin capsules to regulated jurisdictions across the world
  • Optimi Health is a psychedelics-based pharmaceuticals manufacturer with a focus on psilocybin, MDMA and functional mushrooms
  • Optimi Health stock has added 104.35 per cent year-over-year, but remains down by 50 per cent since inception in 2021

Optimi Health (CSE:OPTI), a microcap psychedelics manufacturer, has been awarded a Drug Establishment Licence from Health Canada to produce and sell its MDMA and psilocybin capsules to an Australian client.

The designation certifies that the Vancouver-based company is compliant with Good Manufacturing Practices (GMP), allowing it to manufacture, export and distribute its MDMA and psilocybin capsules to patients with PTSD and treatment-resistant depression under Australia’s Authorised Prescriber Scheme, as well as to regulated jurisdictions across the world.

Australia passed pioneering legislation in 2023 making it the first country in the world to legalize psychedelics to treat mental health conditions. The country will launch its pre-authorized Australian Psychiatrist Portal on June 24, 2024, to approximately 2,800 psychiatrists, granting them ready access to information on the import and export of psychedelics.

Leadership insights

“On a global scale, with the acquisition of the Drug Establishment Licence, Optimi can now provide comprehensive GMP psychedelic drug solutions for worldwide drug commercialization, covering manufacturing, export and distribution. This achievement firmly establishes Optimi as the leader in the rapidly growing psychedelic supply market,” JJ Wilson, chairman and co-founder of Optimi Health, and son to billionaire Lululemon Athletica founder Chip Wilson, said in a statement.

Full story here.

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

Products do not contain psilocybin

Search
Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.